Thus, BCMA-target therapy has gained traction in cancer treatment and will be the treatment of choice, particularly for multiple myeloma. BCMA has co-immunoprecipitation with a master transcription factor (IRF-4) that is involved in myeloma cell survival. Based on product class, BCMA targeted therapies actively involve three major types of immunotherapies: chimeric antigen receptor T-cells (CAR T Cells), bispecific antibodies, and antibody drug conjugates (ADCs).The high cost of multiple combinational drugs as well as maintenance therapy, on the other hand, is expected to stymie the growth of the B-cell maturation Antigen targeted therapies market.
Read More:
https://knackersblogger.blogspot.com/2022/08/increasing-number-of-pipeline-products.html
